Back to news

Cardio Diagnostics to Unveil Non-Obstructive Coronary Artery Disease Data, FDA Breakthrough Device Designation Strategy, and India Launch Update on December 10 Investor Call

Business Wire•17/11/2026•09:17 ET
0

Key Highlights

  • ➤Cardio Diagnostics will present NOCAD detection data on December 10 investor call.
  • ➤Company plans to pursue FDA Breakthrough Device designation for NOCAD detection.
  • ➤Testing commenced in India through partnerships with Dr. Lal PathLabs and Aimil.
  • ➤Call will cover Epi+Gen CHD and PrecisionCHD tests, studies, reimbursement, and growth initiatives.

Cardio Diagnostics to Unveil Non-Obstructive Coronary Artery Disease Data, FDA Breakthrough Device Designation Strategy, and India Launch Update on December 10 Investor Call

Company to present data supporting its technology’s ability to detect non-obstructive coronary artery disease (NOCAD), a condition affecting a large and underserved population that conventional diagnostic pathways often miss, outline its plan to pursue FDA Breakthrough Device designation, and share progress on the commencement of testing in India in partnership with Dr. Lal PathLabs and Aimil

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in